


# TECHNICAL BULLETIN



## $\boxtimes \text{TEST}$ CHANGE $\boxtimes \text{NEW}$ TEST

NOTIFICATION DATE: 03/02/2021 EFFECTIVE DATE: 03/02/2021

## COVID-19 Spike Domain Antibody (COVIDSDAB) COVID-19 Nucleocapsid Antibody (COVIDNCAB)

On the effective date of March 2, 2021, Northwell Health Laboratories will be introducing two new tests: **COVID-19 Spike Domain Antibody Test** and a **separate COVID-19 Nucleocapsid Antibody Test**. Both tests will replace the SARS-CoV-2 IgG Antibody Test.

**The COVID-19 Spike Domain Antibody** test may be reactive in patients due to vaccination, asymptomatic infection, or symptomatic infection.

**The COVID-19 Nucleocapsid Antibody test** may be positive following symptomatic or asymptomatic infection but is very unlikely to be positive following vaccination in the absence of current or past infection.

COVIDSDAB	Roche e 801 Assay		Diasorin Liaison XL Assay	
Methodology:	ECLIA		CMIA	
Specimen Requirements	Serum or Plasma		Serum or Plasma	
	Gold or Mint Green tubes		Gold or Mint Green tubes	
Measures Spike Domain	Yes		Yes	
Antibodies:				
Semi-quantitative Assay:	Yes		Yes	
Analytical Measuring Range:	0.40 to 250.00 U/mL		3.80 to 400.00 AU/mL	
Result Types:	Numeric	Interpretation	Numeric	Interpretation
Reference Range:	Less than / Equal	Negative	Less than / Equal	Negative
2	to 0.79 U/mL	-	to 14.99 AU/mL	-

### **COVID-19 Spike Domain Antibody (COVIDSDAB):**

Test Order: COVIDSDAB

Computer Interface Code: PDM #2153036

#### **COVID-19 Nucleocapsid Antibody (COVIDNCAB):**

COVIDNCAB	Roche 801 Assay		
Methodology:	ECLIA		
Specimen Requirements:	Serum or Plasma Gold or Mint Green tubes		
Measures Nucleocapsid Antibodies:	Yes		
Qualitative Assay:	Yes		
Result Types:	Index	Interpretation	
Reference Range:	Less than / Equal to 0.99 Index	Negative	

Test Order: COVIDNCAB

Computer Interface Code: PDM #2153035